ArticleThe Journal of dermatology2025
Prognosis and Toxicity Stratified by Best Tumor Burden Change in Japanese Patients With Advanced Melanoma Treated With First-Line Programmed Cell Death Protein 1 Monotherapy.
Article in The Journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Severe Immune-Related Adverse Events Associated with Durable Antitumor Responses Following Immune Checkpoint Inhibitor Therapy: Two Case Reports.Cancer management and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in patients with advanced malignant melanoma (MM). However, more than half of patients receiving anti-programmed cell death protein-1 (PD-1) antibody monotherapy still fail to respond, with response rates varying by race and melanoma subtype. Additionally, immune-related adverse events (irAEs) remain a major concern. Although the best overall response based on Response Evaluation Criteria in Solid Tumors version 1.1 is commonly used in clinical trials to assess efficacy, its utility in predicting prognosis and toxicity in real-world clinical settings remains unclear. This retrospective cohort study conducted at Shizuoka Cancer Center in Japan evaluated the association between best tumor burden change (BTBC) in target lesions and prognosis or toxicity among Japanese patients with stage IV MM who received PD-1 monotherapy as first-line treatment. A total of 115 patients were analyzed. Prognosis improved proportionally with reductions in tumor burden from baseline. No significant difference was observed in overall survival between the partial response group and the stable disease group (p = 0.833). However, BTBC < 0% was a significant indicator of a favorable long-term prognosis (p < 0.001). The development of new lesions indicated poor prognosis; however, BTBC ≥ 0% represented poor prognosis regardless of new lesions. Regarding toxicity, the incidence of any-grade irAEs was significantly higher in the BTBC < 0% group than in the BTBC ≥ 0% group (p < 0.001), suggesting that greater tumor shrinkage correlated with increased toxicity. These findings indicate that BTBC may serve as a more accurate predictor of prognosis and toxicity than best overall response in clinical practice. Incorporating BTBC into treatment planning and toxicity monitoring could improve management of stage IV MM, though future prospective studies are needed to establish standardized BTBC criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.